Cytek Biosciences (NASDAQ:CTKB), a leading provider of cell analysis solutions including its flagship Aurora and Northern Lights spectral flow cytometry platforms, announced preliminary, unaudited revenue expectations for the fourth quarter and full year ended December 31, 2025.
The company anticipates full-year 2025 revenue of approximately $201 million.
Fourth-quarter revenue is expected to reach approximately $62 million, representing an 8% increase year-over-year and a 19% sequential increase from the third quarter.
Management attributed the performance to sustained strength in the Services and Reagents segments, robust instrument revenue growth in the Asia Pacific region, and a notable return to positive instrument sales growth in Europe, the Middle East, and Africa (EMEA).
Meanwhile, all figures remain preliminary and are subject to completion of the company's standard year-end close and audit procedures.
Cytek plans to release audited financial results for the fourth quarter and full year 2025, along with detailed 2026 revenue and operating guidance, near the end of February 2026.
The company will also present at the upcoming 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, where management is expected to provide additional commentary on performance, strategic priorities, and market outlook for its expanding portfolio of spectral flow cytometry instruments, reagents, and services.